Alnylam Pharmace. buy StockNews.com
Start price
12.10.25
/
50%
€396.10
Target price
12.10.26
-
Performance (%)
-39.16%
Price
19.06.26
€241.90
Summary
This prediction is currently active. The BUY prediction by StockNews_com for Alnylam Pharmace. is performing very badly with a performance of -39.16%. This prediction currently runs until 12.10.26. The prediction end date can be changed by StockNews_com at any time. StockNews_com has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Performance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Alnylam Pharmace. | -0.982% | -0.982% |
| iShares Core DAX® | 1,35 % | 2,74 % |
| iShares Nasdaq 100 | 3,28 % | 6,51 % |
| iShares Nikkei 225® | 7,43 % | 17,83 % |
| iShares S&P 500 | 1,70 % | 3,10 % |
Comments by StockNews_com for this prediction
In the thread Alnylam Pharmace. diskutieren
Alnylam Pharmaceuticals (NASDAQ:ALNY) was downgraded by analysts at Wall Street Zen from a "strong-buy" rating to a "buy" rating.
Ratings data for ALNY provided by MarketBeat